(Reuters) - NEW YORK, July 19 - The scientific committee of the European Medicines Agency said on Friday it had recommended approval of Pfizer Inc.'s Celsentri, a new type of treatment for HIV whose approval has been delayed in the United States.
The Committee for Medicinal Products said it had recommended marketing approval of Celsentri, known as maraviroc in the United States, for use with other anti-HIV drugs among adult patients infected with the HIV-1 strain of the virus.
Read more at Reuters.com Government Filings News
The Committee for Medicinal Products said it had recommended marketing approval of Celsentri, known as maraviroc in the United States, for use with other anti-HIV drugs among adult patients infected with the HIV-1 strain of the virus.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment